From Reefer Madness to Schedule III: The 90-Year Arc of Cannabis Policy in America

The story of cannabis in America is a story about power, fear, race, science, money, and the slow, grinding machinery of policy change. In 2026, as cannabis sits on the verge of Schedule III reclassification — and lawsuits attempt to reverse even that modest reform — it is worth tracing the arc that brought us here. The journey from Reefer Madness to rescheduling spans nine decades, multiple social movements, and one of the most dramatic policy reversals in modern American history.

The Pre-Prohibition Era (Before 1937)

Cannabis has been present in American life far longer than most people realize. Hemp was a major agricultural crop in colonial America, cultivated by farmers including George Washington and Thomas Jefferson. Cannabis tinctures were widely available in pharmacies throughout the 19th century, prescribed for pain, nausea, and a variety of other ailments.

The plant occupied a mundane space in American life — neither celebrated nor feared, simply present as one of many herbal remedies and industrial materials. That ordinariness would not survive the political currents of the early 20th century.

The Reefer Madness Era (1930s-1960s)

The transformation of cannabis from ordinary plant to existential threat was largely the work of one man: Harry Anslinger, the first commissioner of the Federal Bureau of Narcotics. Appointed in 1930, Anslinger built his agency's political relevance by identifying marijuana as a menace to American society.

Anslinger's campaign was overtly racial. He promoted narratives linking marijuana to Mexican immigrants and Black jazz musicians, using racist language that would be unprintable today. His congressional testimony portrayed cannabis as a drug that caused insanity, violence, and moral degradation — claims with no scientific basis.

The 1936 propaganda film "Reefer Madness" — originally titled "Tell Your Children" — dramatized these claims with scenes of marijuana-induced murder, suicide, and psychosis. Though it was later embraced as camp by cannabis advocates, the film reflected mainstream attitudes of its era. Fear was the primary tool of cannabis prohibition, and it worked.

The Marihuana Tax Act of 1937 effectively criminalized cannabis at the federal level, not through an outright ban but through a tax structure designed to make legal possession practically impossible. The American Medical Association opposed the legislation, noting that cannabis had legitimate medical uses, but was overruled.

The Nixon Years and Schedule I (1970-1980)

The modern era of cannabis prohibition began with Richard Nixon. The Controlled Substances Act of 1970 created the scheduling system that classified drugs by their perceived danger and medical utility. Cannabis was placed in Schedule I — the most restrictive category, reserved for substances with "high potential for abuse" and "no currently accepted medical use."

The scheduling was meant to be temporary. Nixon appointed the Shafer Commission to study marijuana and recommend a permanent classification. The commission's 1972 report recommended decriminalization, concluding that marijuana did not pose the dangers that justified criminal penalties.

Nixon rejected the commission's findings. His domestic policy advisor, John Ehrlichman, later admitted in a 1994 interview that the administration's drug policy was designed to target political opponents. The War on Drugs that followed would devastate communities of color for the next five decades.

The War on Drugs (1980s-1990s)

The Reagan administration escalated cannabis enforcement dramatically. Nancy Reagan's "Just Say No" campaign reinforced the idea that all drug use was equally dangerous. Mandatory minimum sentencing laws imposed harsh prison terms for marijuana possession and distribution.

The racial disparities in enforcement were staggering. Despite roughly equal rates of cannabis use across racial groups, Black Americans were arrested for marijuana offenses at nearly four times the rate of white Americans. These arrests created criminal records that followed people for decades, affecting employment, housing, education, and civic participation.

By the early 1990s, the United States was incarcerating more people for drug offenses than any other country. Cannabis accounted for a significant portion of these arrests — hundreds of thousands per year. The human cost was enormous, and the policy failed by its own metrics: cannabis use did not decline.

The Medical Revolution (1996-2012)

California's Proposition 215, passed by voters in 1996, marked the first crack in federal prohibition. The Compassionate Use Act allowed patients with serious illnesses to use cannabis with a doctor's recommendation, directly contradicting the Schedule I classification that claimed cannabis had no medical value.

The federal government under both Clinton and Bush administrations continued to enforce prohibition, raiding medical dispensaries in California and other states that followed with their own medical programs. The conflict between state and federal law created legal confusion that persisted for years.

By 2012, eighteen states and the District of Columbia had established medical cannabis programs. The scientific evidence supporting medical use — particularly for chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea — continued to accumulate, making the Schedule I classification increasingly difficult to defend on scientific grounds.

The Legalization Wave (2012-2024)

Colorado and Washington made history in November 2012 when voters approved full recreational legalization. The sky did not fall. Teen use did not spike. Crime did not surge. The predictions of prohibition advocates did not materialize.

Instead, the states developed functioning regulatory systems, generated significant tax revenue, and created legal industries that employed thousands. Other states watched, learned, and followed.

Oregon and Alaska legalized in 2014. California, the birthplace of medical cannabis, approved recreational use in 2016. By 2020, legalization had spread across geographic and political boundaries. Red states like Montana and South Dakota voted to legalize, challenging the assumption that cannabis reform was a progressive cause.

The pace accelerated through the early 2020s. State after state voted to legalize, through both ballot initiatives and legislative action. By 2024, the majority of Americans lived in states with some form of legal cannabis.

The Rescheduling Battle (2024-2026)

The movement to reschedule cannabis at the federal level gained decisive momentum when the Department of Health and Human Services recommended reclassification from Schedule I to Schedule III in 2023. The Department of Justice initiated the rulemaking process, and despite bureaucratic delays and political opposition, the reclassification moved forward.

Schedule III represents a seismic shift. While it does not legalize cannabis, it acknowledges that the plant has accepted medical use and a lower potential for abuse than Schedule I substances. For the cannabis industry, the practical implications are enormous: Schedule III eliminates the Section 280E tax penalty that has prevented cannabis businesses from deducting ordinary business expenses, potentially saving the industry billions.

Green Thumb Industries became the first multi-state operator to file for DEA Schedule III registration, signaling the industry's preparation for a new regulatory framework.

But the rescheduling has not gone unchallenged. Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association filed a lawsuit seeking to reverse the reclassification, represented by a firm where former Trump administration Attorney General William Barr is a partner. The legal battle over rescheduling continues to play out in 2026, adding uncertainty to an industry already navigating complex regulatory terrain.

Most recently, the Senate dropped a House rider that would have blocked rescheduling, clearing the path for the Schedule III transition to proceed. But legal challenges remain active, and the outcome is far from guaranteed.

The Countermovement

Even as federal policy inches toward reform, a countermovement has emerged at the state level. Several states are considering ballot measures that would roll back existing legalization programs, driven by concerns about commercialization, youth access, and public health impacts.

This countermovement reflects a genuine tension in the legalization debate. While public support for legalization remains strong — consistent polling shows majority support across partisan lines — the implementation of legal markets has not been universally positive. Some communities feel overwhelmed by dispensary density, and concerns about impaired driving and adolescent use persist.

Where We Stand

In 2026, American cannabis policy exists in a state of productive contradiction. The federal government is reclassifying cannabis even as lawsuits seek to prevent it. States are legalizing even as other states attempt to reverse course. The industry is growing even as it faces class action lawsuits and regulatory uncertainty.

What has not changed is the direction of the arc. From Reefer Madness to Schedule III, the trajectory bends toward normalization. The racist foundations of prohibition have been exposed. The medical evidence is overwhelming. The economic benefits are documented. The public has spoken, repeatedly and clearly, in favor of reform.

The 90-year journey is not over. Full federal legalization, comprehensive expungement of cannabis convictions, and equitable access to the legal industry remain aspirational goals rather than accomplished facts. But the distance traveled — from a propaganda film that portrayed cannabis as a pathway to murder, to a federal acknowledgment that the plant has legitimate medical value — represents one of the most dramatic policy reversals in American history.

The story of cannabis in America is ultimately a story about how societies change their minds. It happens slowly, painfully, and incompletely. But it happens.